Collegium Pharmaceutical (COLL) Stock Price, News & Analysis

Company Overview

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Key Stats

• Today's Range: $27.84 to $29.66
• 50-Day Range: $24.67 to $30.56
• 52-Week Range: $23.23 to $42.29
• Volume: 561,658 shs
• Average Volume: 436,387 shs
• Market Capitalization: $928.29 million
• P/E Ratio: 12.45
• Dividend Yield: N/A
• Price Target: $43.80
• Consensus Rating: Moderate Buy

Collegium Pharmaceutical Stock Analysis - MarketRank™

Collegium Pharmaceutical scored higher than 79% of companies evaluated by MarketBeat, and ranked 201st out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Collegium Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Collegium Pharmaceutical has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 7.12%

Earnings Growth

Earnings for Collegium Pharmaceutical are expected to grow by 7.12% in the coming year, from $5.62 to $6.02 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Collegium Pharmaceutical is 12.45, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 22.19.

Price to Earnings Ratio vs. Sector

The P/E ratio of Collegium Pharmaceutical is 12.45, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 25.14.

Price to Book Value per Share Ratio

Collegium Pharmaceutical has a P/B Ratio of 4.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.46% of the float of Collegium Pharmaceutical has been sold short.

Short Interest Ratio / Days to Cover

Collegium Pharmaceutical has a short interest ratio ("days to cover") of 11.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Collegium Pharmaceutical has recently decreased by 1.32%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Collegium Pharmaceutical does not currently pay a dividend.

Dividend Growth

Collegium Pharmaceutical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.0 / 5
• Environmental Score: -2.78

Percentage of Shares Shorted

14.46% of the float of Collegium Pharmaceutical has been sold short.

Short Interest Ratio / Days to Cover

Collegium Pharmaceutical has a short interest ratio ("days to cover") of 11.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Collegium Pharmaceutical has recently decreased by 1.32%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.63

News Sentiment

Collegium Pharmaceutical has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 20 news articles for Collegium Pharmaceutical this week, compared to 5 articles on an average week.

Search Interest

2 people have searched for COLL on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Collegium Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Collegium Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,334,994.00 in company stock.

Percentage Held by Insiders

Only 2.51% of the stock of Collegium Pharmaceutical is held by insiders.

COLL Stock Analysis - Frequently Asked Questions

How have COLL shares performed this year?

Collegium Pharmaceutical's stock was trading at $28.65 at the start of the year. Since then, COLL stock has increased by 0.8% and is now trading at $28.89.
View the best growth stocks for 2025 here.

How were Collegium Pharmaceutical's earnings last quarter?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) issued its quarterly earnings results on Thursday, February, 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating analysts' consensus estimates of $1.54 by $0.09. The specialty pharmaceutical company earned $181.95 million during the quarter, compared to the consensus estimate of $179.68 million. Collegium Pharmaceutical had a trailing twelve-month return on equity of 104.67% and a net margin of 14.78%.
Read the conference call transcript.

When did Collegium Pharmaceutical IPO?

Collegium Pharmaceutical (COLL) raised $75 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

Who are Collegium Pharmaceutical's major shareholders?

Collegium Pharmaceutical's top institutional investors include Vanguard Group Inc. (6.99%), Principal Financial Group Inc. (4.90%), Emerald Advisers LLC (2.57%) and Massachusetts Financial Services Co. MA (2.22%). Insiders that own company stock include Joseph Ciaffoni, Colleen Tupper, Scott Dreyer, Shirley R Kuhlmann, Thomas B Smith, Garen G Bohlin and Michael Thomas Heffernan.
View institutional ownership trends.

How do I buy shares of Collegium Pharmaceutical?

Shares of COLL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Collegium Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Collegium Pharmaceutical investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Arista Networks (ANET), Netflix (NFLX) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 2/27/2025
• Today: 5/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:COLL
• CIK: 1267565
• Web: www.collegiumpharma.com
• Phone: (781) 713-3699
• Fax: N/A
• Employees: 210
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $43.80
• High Stock Price Target: $50.00
• Low Stock Price Target: $37.00
• Potential Upside/Downside: +51.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $1.86
• Trailing P/E Ratio: 12.45
• Forward P/E Ratio: 5.14
• P/E Growth: N/A
• Net Income: $48.15 million
• Net Margins: 14.78%
• Pretax Margin: 21.36%
• Return on Equity: 104.67%
• Return on Assets: 18.38%

Debt

• Debt-to-Equity Ratio: 3.43
• Current Ratio: 0.97
• Quick Ratio: 0.88

Sales & Book Value

• Annual Sales: $631.45 million
• Price / Sales: 1.47
• Cash Flow: $10.47 per share
• Price / Cash Flow: 2.76
• Book Value: $5.99 per share
• Price / Book: 4.82

Miscellaneous

• Outstanding Shares: 32,132,000
• Free Float: 30,966,000
• Market Cap: $928.29 million
• Optionable: Optionable
• Beta: 0.63